David Z I Cherney
Overview
Explore the profile of David Z I Cherney including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
247
Citations
6366
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Glucagon-like peptide-1 receptor agonists to improve cardiorenal outcomes: data from FLOW and beyond
Faruque L, Yau K, Cherney D
Curr Opin Nephrol Hypertens
. 2025 Mar;
PMID: 40047207
Purpose Of Review: Glucagon-like peptide-1 receptor agonists (GLP1RA), initially approved for glycemic control in type 2 diabetes mellitus (T2DM), have emerged as agents for weight loss, cardiovascular and kidney protection....
2.
Beal B, Buizen L, Yeung E, Heath L, Houston L, Cherney D, et al.
Nephrol Dial Transplant
. 2025 Mar;
PMID: 40036884
Background: Insulin is a mainstay treatment for diabetes, but its use is associated with weight gain and hypoglycaemia. Data on the effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on insulin...
3.
Cherney D, Frederich R, Pratley R, Cosentino F, Dagogo-Jack S, Pong A, et al.
Kidney Dis (Basel)
. 2025 Mar;
11(1):63-74.
PMID: 40028005
Introduction: VERTIS CV was a placebo-controlled cardiovascular (CV) outcome trial evaluating the sodium-glucose cotransporter 2 inhibitor ertugliflozin in patients with type 2 diabetes and established atherosclerotic CV disease. The aim...
4.
Leon-Jimenez D, Sridhar V, Lopez-Mendoza M, Scholtes R, Schmieder R, Cherney D, et al.
Clin Kidney J
. 2025 Feb;
18(1):sfae370.
PMID: 40008354
The progressive loss of kidney function in diabetes mellitus is partly attributable to the occurrence of glomerular hyperfiltration. Consequently, therapeutic interventions that lower intra-glomerular pressure are a cornerstone of treatment...
5.
Sridhar V, Kugathasan L, Lovblom L, Huajing N, Lanctot S, Maahs D, et al.
J Am Soc Nephrol
. 2025 Feb;
PMID: 39982799
No abstract available.
6.
Aggarwal R, Bhatt D, Szarek M, Cannon C, Leiter L, Inzucchi S, et al.
Lancet Diabetes Endocrinol
. 2025 Feb;
PMID: 39961315
Background: Sodium-glucose co-transporter (SGLT)-2 inhibitors have shown consistent benefit in improving heart failure-related outcomes but not ischaemic cardiovascular events such as myocardial infarction or stroke. We assessed if the dual...
7.
Bapat P, Budhram D, Bakhsh A, Abuabat M, Verhoeff N, Mumford D, et al.
Diabetes Care
. 2025 Feb;
PMID: 39950992
Objective: We aimed to determine whether diabetes complications, such as kidney disease that may impair acid-base buffering capacity, independently predict the risk of subsequent diabetic ketoacidosis (DKA). Research Design And...
8.
Nardone M, Kugathasan L, Sridhar V, Dutta P, Campbell D, Layton A, et al.
Clin J Am Soc Nephrol
. 2025 Feb;
PMID: 39918875
No abstract available.
9.
Nardone M, Yau K, Kugathasan L, Odutayo A, Mohsen M, Ouimet J, et al.
Nephrol Dial Transplant
. 2025 Feb;
40(Supplement_1):i47-i58.
PMID: 39907540
Abstract: Despite recent advancements in the treatment of chronic kidney disease (CKD), identifying novel therapies beyond guideline-directed therapies that reduce residual cardiorenal risk remains imperative. In this review, we highlight...
10.
Pandey A, Kolkailah A, McGuire D, Frederich R, Cater N, Cosentino F, et al.
Eur J Heart Fail
. 2025 Jan;
PMID: 39792342
Aims: In VERTIS CV, ertugliflozin was associated with a 30% risk reduction for adjudication-confirmed, first and total hospitalizations for heart failure (HHF) in participants with type 2 diabetes and atherosclerotic...